SHORT ANSWER
No. A checkout attestation is one more written statement, and FDA reads intended use from the whole presentation, not from the statement placed last. In the peptide warning letters, FDA quotes every variant of research-only wording, on labels, product pages, and terms, and then sets them aside because the product descriptions on the same site described effects in people.
This material is general educational information as of the “last reviewed” date. It is not legal advice and may not reflect later developments or facts specific to your business. Links are provided so readers can inspect the primary or official sources.
01 / THE VARIANTS
Every phrasing has been quoted, and set aside, the same way
Sellers tend to assume the exact wording matters: that “research purposes only” is stronger than “research use only,” or that adding “not for human consumption” or a full not-intended-to-treat line closes the gap. The letters do not distinguish. FDA quotes the site’s own phrasing inside one stock sentence, then states that website evidence establishes intended human use. Among the phrasings quoted in RUO Clear’s corpus of 185 letters:
- “research purposes only” and “not for human consumption or clinical use” (Prime Peptides, December 2024)
- “laboratory research purposes only” and “not for human consumption, medical use or veterinary use” (Prime Sciences, March 2026)
- “RESEARCH USE ONLY” and “INTENDED AS A RESEARCH CHEMICAL ONLY” (Summit Research Peptides, December 2024)
- “research chemicals only” and “not for human consumption” (US Chem Labs, February 2024)
- “[F]or research use only” and “[F]or research purposes only,” both on one site (SARMS America, December 2025)
- “research use only,” “not for human consumption,” “lab purposes only,” and “not intended to diagnose, cure, mitigate, treat or prevent disease,” all four on one site (USApeptide.com, February 2025)
In RUO Clear’s tagging of the corpus, fifteen letters quote research-only or not-for-human-consumption wording and expressly disregard it. None treats the wording as a mitigating factor. The count reflects how the letters were tagged during compilation, not an FDA statistic.
02 / WHY IT DOES NOT FILTER
An attestation is a statement, not a filter
A checkout gate feels different from a footer disclaimer because the buyer, not the seller, makes the statement. The regulation does not turn on who clicks. Under 21 CFR § 201.128, intended use is the objective intent of the persons legally responsible for the product, shown by their labeling, advertising, written statements, and the circumstances of distribution. The seller wrote the product page. The seller built the checkbox. Both are the seller’s statements, and FDA reads them together.
That is why the letters can quote a boundary statement and, in the same paragraph, cite a product description about appetite, glucose, or muscle repair as the evidence that controls. The attestation did not remove those descriptions. It sat beside them, and the letter says which one FDA believed.
Under 21 U.S.C. § 321(g)(1), the question is what the product is intended to be used for. A buyer’s promise not to use it in a person does not change what the seller said it does in a person.
03 / WHAT BUYER CONTROLS CAN DO
Buyer controls change who can buy, not what the page says
None of this means attestation and gating are pointless. They are a recommended control, and they do real work: they narrow who can reach checkout, they create a record that a stated policy exists and was applied, and they give a reviewer something to inspect beyond copy. A payment provider reviewing an application may ask what preventive measures a store applies, and a documented gate is an answer.
What a gate cannot do is retroactively change the product page a buyer read before reaching it. If the description promised fat loss, the gate is a promise stacked on a promise. The control is only as credible as the pages around it.
Treat the attestation as one of several controls, keep a record of when it was added and what it says, and do not describe it anywhere as the thing that makes the storefront acceptable. That last claim is exactly the kind of statement a reviewer would test against the rest of the site.
RUO Clear cannot tell you that a gate satisfies any regulator or provider. It can tell you the gate exists, what it says, and whether the surrounding pages contradict it.
04 / WHERE THE CONTRADICTION LIVES
The product page and the checkout usually disagree
In the letters, the boundary wording and the outcome claims are almost never on the same page. The research-only line lives on the label image, the footer, the terms page, or the cart. The outcome language lives in the product description, the collection page, the blog, and the social feed. A buyer moving through the site reads the claims first and the boundary last.
FDA reads the site in the opposite order from how a seller built it. The seller added the disclaimer to protect the claims. The letter treats the claims as the evidence and the disclaimer as an acknowledgment that the seller knew what the claims meant.
The practical test is simple: put the product description and the attestation text side by side. If a stranger would say they describe two different products, the storefront has a contradiction, and no wording change to the attestation resolves it.
05 / WHAT TO REVIEW
Review the pages the attestation is supposed to cover
Because the gate cannot cure the pages before it, the review has to start with those pages. Work through each surface, and record what was found and what was changed.
- Every product description, for effects described in people or “test subjects”
- Collection names, category names, and product names that name an outcome or an approved drug
- Terms of sale and attestation text, for promises about what the products do or who they are for
- The label image itself, which FDA quotes as “product labeling”
- Blog posts, guides, and linked social accounts, which the letters attribute to the seller
- Whether the attestation is enforced (a required control) or decorative (a pre-checked box)
- A dated record of when each boundary statement and control was added or changed
QUESTIONS
Related questions
Should I make the attestation stronger or longer?
Length is not the issue. USApeptide.com carried four separate boundary statements and FDA quoted all four before setting them aside. Fix the product descriptions the attestation is meant to qualify; keep the attestation short and accurate.
Does requiring a lab name or institution at checkout change the analysis?
It changes who can buy and it creates a record. It does not change what the product page says. FDA has not treated buyer credentials as a substitute for the seller’s own statements about the product.
Is an attestation worth keeping at all?
Yes, as one control among several. It narrows the buyer pool, documents a policy, and gives a reviewer something concrete to inspect. Its value depends entirely on whether the rest of the site agrees with it.
SOURCES
Sources cited
Each source is listed with its class so government authority, agency guidance, enforcement examples, and private policy are never blended into one rule.
Quotes “research purposes only” and “not for human consumption or clinical use,” then finds intended human use from the website.
Quotes “RESEARCH USE ONLY” and “INTENDED AS A RESEARCH CHEMICAL ONLY” across multiple websites.
Quotes two variants, “[F]or research use only” and “[F]or research purposes only,” from one site.
Quotes “laboratory research purposes only” and a not-for-human, medical, or veterinary use line.
Lists four separate boundary statements from the site before setting them aside.
Objective intent of the persons legally responsible, shown by labeling, advertising, written statements, and circumstances of distribution.
A product is a drug based on the use it is intended for.